Sermorelin

Sermorelin is one of the few compounds in this library that was genuinely an approved medicine. Two FDA approvals, withdrawn in 2009. That history is real, and it is also narrower than it sounds: the approved uses were growth hormone deficiency in children and a test of pituitary function. Neither was an adult performance, sleep, or body-composition use.

So the evidence here is unusual for this library. There is a proper randomised trial record, and most of it is from the 1980s and 1990s, and what it largely shows is a compound that worked less well than the drug it was competing against.

Sermorelin is a synthetic copy of the first 29 amino acids of growth hormone-releasing hormone. That fragment is the shortest one that retains full biological activity, which was established in healthy volunteers in the mid-1980s by comparing it directly against the longer 1-40 and 1-44 forms and finding no difference in the growth hormone response.

It is cleared quickly. Measured by constant infusion in ten healthy men, the disappearance half-time is about four minutes. The growth hormone response outlasts the peptide by hours, which is the point of the mechanism rather than a contradiction of it.

No FDA-approved sermorelin product exists today. Anything currently sold under the name is compounded or supplied outside that framework.

What It Actually Does at the Pituitary

Sermorelin binds the GHRH receptor on pituitary somatotrophs and prompts them to release growth hormone they have already made. It does not replace growth hormone; it asks for it. That distinction is why the compound depends on a pituitary that still works, and why it failed in children whose problem sat at the pituitary rather than above it.

Amplitude, Not Timing

The cleanest human demonstration is a controlled clamp study in which continuous infusion roughly tripled the height of growth hormone pulses while leaving their timing untouched. Somatostatin sets when the pulses happen; GHRH sets how big they are. This is a precise, well-characterised mechanism, and it is the strongest thing on this page.

Where the Chain Breaks

A larger growth hormone pulse is not the same as a downstream effect. In the placebo-controlled crossover in healthy older adults, sermorelin raised peak growth hormone about sixfold over placebo, and IGF-1 did not change consistently. In healthy elderly men given it nightly for six weeks, nocturnal growth hormone release rose and IGF-1, IGFBP-3 and growth hormone binding protein all stayed put. The mechanism is real. The step from mechanism to outcome is where the evidence stops.

Calling it FDA approved. It was. It is not. FDA withdrew approval of both applications effective 18 June 2009, and no approved product has existed since.

Reading the 2013 FDA determination as an endorsement. FDA did formally find that the products were not withdrawn for reasons of safety or effectiveness. That is a finding about why a company stopped selling something. It is not a judgement that the compound is safe or effective for any use it was never approved for.

Citing the anti-aging trials. The two studies that anchor that claim used a different molecule. Anyone repeating them as sermorelin evidence has not checked the compound in the methods section.

Treating a growth hormone rise as the result. The rise is well established. In healthy adults it has not reliably carried through to IGF-1, body composition, or anything else that was measured.

Generalising from children with a deficiency. Almost the entire efficacy record is in children whose growth hormone axis was underactive. That is the population where a signal to the pituitary has the most room to do something.

Immunogenicity was common, not rare. Thirty-nine of forty children in the randomised comparison developed anti-GHRH antibodies, and antibodies appeared within six weeks on the intranasal route in a separate study.

The response declines with continued use. Multiple studies found the growth hormone response falling over months, in one case to complete suppression in a single child. Anything that stimulates a feedback-regulated axis is subject to this.

There is no approved product, so there is no approved manufacturer. The historical trial evidence was generated with a pharmaceutical product that no longer exists. Identity, purity and dose of anything sold today are a separate question from anything on this page.

The FDA review documents are largely unavailable. The clinical and statistical reviews for both applications predate FDA's online archive, and the labelling was withheld. The public evidence base is the published literature, not the regulatory file.

It is prohibited in sport. Named among GHRH analogues on the WADA list.

Sermorelin is a good example of why this library ranks evidence rather than reputation. It has more genuine human trial data behind it than most compounds here, and that data mostly reports a compound that did less than the alternative, in a population that is not the audience reading about it.

The honest summary is three sentences. The mechanism is real and precisely characterised. The efficacy record is in growth-hormone-deficient children, where it worked and worked less well than growth hormone. In healthy adults, the one study that measured body composition and IGF-1 found no change in either.

None of that makes it a fraud, and this page is not trying to make it one. It makes it a compound whose evidence points somewhere specific and narrow, and whose marketing points somewhere else entirely.

Not an approved medicine today. It was one until 2009, for two indications, neither of them adult optimisation.

Not the compound in the anti-aging studies. Those used a norleucine-substituted analog.

Not demonstrated to change body composition in healthy adults. The study that looked found no change in DEXA muscle or fat.

Not a gentler growth hormone. It is a different intervention with a different evidence base, not a milder version of one.

Not interchangeable with tesamorelin. Tesamorelin is a separate, currently approved GHRH analog with its own trial programme, and its studies are routinely miscited as sermorelin evidence.

This page sits at Controlled human trials because randomised trials in people are cited on it, which is a statement about the sources here and not a verdict that the compound works. Read the tier and the findings together: the trials exist, they are decades old, they are mostly in children, and several of their headline results are unfavourable.

Aeternus treats sermorelin as the clearest available illustration of a gap this library exists to show. A compound can have a legitimate medical history, a well-understood mechanism, and a real trial record, and still not support the claims made for it, because the trials asked a different question in a different population. Education before intervention.